<DOC>
	<DOCNO>NCT00118365</DOCNO>
	<brief_summary>This randomized phase III trial study eflornithine sulindac see well work compare placebo prevent colorectal cancer patient colon polyp . Chemoprevention use certain drug keep cancer forming , grow , come back . The use eflornithine sulindac may prevent colorectal cancer . It yet know whether eflornithine sulindac effective placebo prevent colorectal cancer</brief_summary>
	<brief_title>Eflornithine Sulindac Preventing Colorectal Cancer Patients With Colon Polyps</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare rate new adenomatous polyp formation patient history adenomatous polyp colon treat eflornithine sulindac v placebo . II . Correlate effect eflornithine sulindac polyamine prostaglandin content flat mucosa rate new adenoma formation patient . III . Compare rate side effect patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord participate center aspirin use ( yes v ) . Patients receive oral double placebo daily 4 week . Patients 70 % compliant pill measurement self report randomize 1 2 treatment arm . Arm I : Patients receive oral double placebo daily . Arm II : Patients receive oral eflornithine ( DFMO ) oral sulindac daily . In arm , treatment continue 36 month absence unacceptable toxicity development invasive malignancy .</detailed_description>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Criteria : History &gt; = 1 surgically resect adenomatous polyp colon measure &gt; = 3 mm within past 5 year Screening colonoscopy perform within past 6 month All polyp must remove colonoscopy , pathologically examine , archive No prior surgical resection remove &gt; 40 cm colon No personal family history familial polyposis hereditary nonpolyposis colon cancer SWOG 01 Bilirubin = &lt; 2.0 mg/dL AST ALT = &lt; 2 time normal Creatinine = &lt; 1.5 mg/dL Urine protein = &lt; , urine cast 03 , urine WBC RBC count 05 cell urinalysis No history inflammatory bowel disease No gastric duodenal ulcer within past 12 month Gastric duodenal ulcer adequately treat &gt; 24 month ago allow No symptomatic gastric duodenal ulcer Not pregnant nursing Negative pregnancy test Must regional geographic stability next 36 month Pure tone audiometry evaluation normal Patients &gt; = 20 dB uncorrectable hearing loss ( age ) 2 contiguous frequency allow No invasive malignancy within past 5 year except adequately treat nonmelanoma skin cancer , level I ( Breslow &lt; 0.76 mm ) cutaneous melanoma , Duke 's A colon cancer , stage I cervical cancer , stage 0 chronic lymphocytic leukemia No severe metabolic disorder No significant acute chronic disease would preclude study participation No history abnormal wound heal repair No condition would confer risk abnormal wound heal repair No history allergy NSAIDs eflornithine No concurrent chemotherapy No concurrent corticosteroid regular predictable intermittent basis No concurrent radiotherapy Concurrent calcium supplement ( = &lt; 1,000 mg/day ) allow Concurrent lipidlowering drug ( i.e. , highdose statin ) allow No concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) regular predictable intermittent basis Concurrent aspirin cardiovascular prophylaxis ( i.e. , 81 mg/day ) allow No concurrent anticoagulants regular predictable intermittent basis No concurrent treatment gastric duodenal ulcer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>